Amendment No. 1 to Third Amended and Restated Promissory Note between Chromocell Therapeutics Corporation and 3i, LP
Chromocell Therapeutics Corporation and 3i, LP have agreed to amend their existing promissory note by extending the maturity date to October 10, 2023. In exchange for this extension, Chromocell will pay 3i, LP an additional $100. All other terms of the original note remain unchanged and in effect.
Exhibit 4.8
CHROMOCELL THERAPEUTICS CORPORATION
Amendment No. 1 to Third Amended and Restated Promissory Note
| Face Amount: $450,000.00 | September 26, 2023 |
| Purchase Price: $300,000.00 | New York, NY |
Chromocell Therapeutics Corporation, a Delaware corporation (the “Borrower”), and 3i, LP, its successors or assigns (the “Lender”), pursuant to that certain Third Amended and Restated Promissory Note, dated August 13, 2023 (the “Note”), do hereby agree to amend the Note to extend the Maturity Date (as defined in the Note) to October 10, 2023.
In consideration thereof, the Company agrees to pay to Lender the amount of One Hundred Dollars ($100).
Except as specifically set forth herein, Borrower and Lender hereby confirm that the terms of the Note remain unmodified and in full force and effect.
| BORROWER: | |||
| Chromocell Therapeutics Corporation | |||
| By: | /s/ Francis Knuettel II | ||
| Name: Francis Knuettel II | |||
| Title: Chief Financial Officer | |||
| LENDER: | |||
| 3i, LP | |||
| By: | /s/ Maier J. Tarlow | ||
| Name: Maier J. Tarlow | |||
| Title: Manager On Behalf Of The GP | |||
